Liao CT, Yang CT, Chen PH, et al. Association of adherence to antiretroviral therapy with economic burden of cardiovascular disease in HIV-infected population. Eur J Prev Cardiol. Epub ahead of print 2 March 2020. DOI:10.1177/2047487320908085.
2.
FreibergMSChangCCKullerLH, et al.
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med2013;
173: 614–622.
3.
PhanBAWeigelBMaY, et al.
Utility of 2013 American College of Cardiology/American Heart Association cholesterol guidelines in HIV-infected adults with carotid atherosclerosis. Circ Cardiovasc Imaging2017;
10.
4.
Friis-MøllerNRyomLSmithC, et al.
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D: A: D) study. Eur J Prev Cardiol2016;
23: 214–223
5.
BakerJVSharmaSAchhraAC, et al.
Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial.J Am Heart Assoc2017;
6: e004987.
6.
BavingerCBendavidENiehausK, et al.
Risk of cardiovascular disease from antiretroviral therapy for HIV: A systematic review. PLoS One2013;
8: e59551.
7.
BalloccaFD’AscenzoFGiliS, et al.
Cardiovascular disease in patients with HIV. Trends Cardiovasc Med2017;
27: 558–563.
